FDA approves first TA-TMA therapy — Omeros’ Yartemlea cleared

The FDA approved Omeros Corporation’s Yartemlea (narsoplimab), the first approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA‑TMA). The approval followed a PDUFA review and designates narsoplimab as a new option for a life‑threatening transplant complication with limited prior treatments. Clinicians and transplant centers will now have a targeted monoclonal antibody therapy to manage TA‑TMA.